Aetna considers bone mass measurement using the established techniques listed below medically necessary for members who meet any of the following criteria:
Individuals being monitored to assess the response to or efficacy of osteoporosis drug therapy (only dual-energy x-ray absorptiometry is considered medically necessary for this indication); or
Individuals receiving (or expected to receive) glucocorticoid (steroid) therapy equivalent to 5 mg of prednisone or greater, per day, for more than 3 months; or
Individuals with celiac sprue; or
Individuals with primary hyperparathyroidism; or
Individuals with vertebral abnormalities as demonstrated by an x-ray to be indicative of osteoporosis, osteopenia, or vertebral fracture; or
Men greater than 50 years of age with specific risk factors for osteoporosis (i.e., low body weight, weight loss, or physical inactivity) (Note: covered for members with preventive services benefits only); or
Men with hypogonadism or receiving androgen deprivation treatment (e.g., leuprolide, and goserelin); or
Non-traumatic (fragility) fractures; or
Screening of men greater than 70 years of age (Note: covered for members with preventive services benefits only); or
Screening of women who have been determined to be estrogen-deficient (peri- or post-menopausal) (Note: covered for members with preventive services benefits only); or
Women on long-term (i.e., longer than 2 years) Depo-Provera Contraceptive Injection (CI) therapy; or
Women on long-term anticonvulsant therapy (e.g., phenytoin, and phenobarbital); or
Women with hyperthyroidism.
Aetna considers bone mass measurement experimental and investigational for all other indications because its effectiveness for indications other than the ones listed above has not been established.
Repeat bone mass measurements are usually not indicated more frequently than once every 2 years. More frequent bone mass measurements may be considered medically necessary in any of the following circumstances:
For a confirmatory baseline bone mass measurement to permit monitoring of individuals in the future if the initial bone mass test was performed with a technique that is different from the proposed testing method; or
Monitoring of individuals on long-term glucocorticoid (steroid) therapy or anticonvulsant therapy of more than 3 months duration; or
Monitoring of individuals with uncorrected primary hyperparathyroidism.
Repeat bone mass measurement has no proven value for other indications.
Aetna considers simultaneous axial (central) and appendicular (peripheral) bone mass measurements medically necessary only in the following limited circumstances:
An axial scan is considered medically necessary to get a baseline measurement for monitoring if osteoporosis is identified with an appendicular scan; or
Appendicular measurements are considered medically necessary when artifacts obscure measurement at the axial skeleton; or
Member is diagnosed with uncorrected primary hyperparathyroidism.
Simultaneous axial and appendicular bone mass measurements have no proven value for other indications.
The following methods are established procedures of bone mass measurements of the axial or appendicular (peripheral) skeleton:
Dual energy X-ray absorptiometry (DEXA or DXA);
Quantitative computed tomography (QCT);
Radiographic absorptiometry (photodensitometry);
Single energy X-ray absorptiometry (SEXA);
Ultrasound bone mineral density studies (e.g., Achilles + Bone Sonometer, Sahara, SoundScan).
Aetna considers bone mass measurement by dual photon absorptiometry (DPA), dual X-ray and laser (DXL), or single photon absorptiometry (SPA) experimental and investigational because their effectiveness for this indication has not been established.
Aetna considers screening for vertebral fractures with dual energy x-ray absorptiometry (DEXA or DXA) (also known as morphometric x-ray absorptiometry) as an adjunct to bone mineral density measurement experimental and investigational. There is a lack of clinical trial evidence showing that individuals with vertebral fractures on DXA but with bone mineral density levels above treatment thresholds benefit from pharmacologic treatment (BCBSA, 2004; BCBSA, 2006). Note: Examples of vertebral fracture assessment application packages that have received 510(k) marketing clearance are the Instant Vertebral Assessment (IVA) (Hologic, Inc.) and Dual Energy Vertebral Assessment (DVA) (previously known as Lateral Vertebral Assessment (LVA) (GE Lunar Medical Systems).
This policy is adapted from guidelines for bone mineral density (BMD) screening from the Centers for Medicare and Medicaid Services, National Institutes of Health, the American Association of Clinical Endocrinologists, and the American Gastroenterological Association.
Osteoporosis is a cause of significant morbidity and mortality in men as well as post-menopausal women. It is a disease characterized by low bone density and increased bone fragility, which reduce bone strength. Post-menopausal osteoporosis is due to rapid bone loss that occurs with the decline in endogenous estrogen following menopause. However, in both men and women, increasing age and low BMD are 2 important independent risk factors for an initial vertebral or non-vertebral fracture. While the incidence of vertebral fracture increases with age, the increase is greater among women than men; however, mortality after fracture is higher among men. According to the literature, the diagnostic criteria for post-menopausal osteoporosis in women are well established; however, there is ongoing debate about the appropriate T-scores and BMD thresholds to diagnose osteoporosis in men (Bonnick, 2006).
Primary osteoporosis is an aged-related disease characterized by low bone mass, microarchitectural deterioration of bone tissue leading to enhanced bone fragility, and a consequent increase in fracture risk in the absence of other recognizable causes of bone loss. Present intervention efforts are directed largely at identifying those peri-menopausal women who are the most likely to be at risk for future fracture, and providing preventive bisphosphonate therapy along with adequate calcium intake and weight bearing exercise. Secondary osteoporosis has an identifiable cause of bone loss. Many, but not all, patients receiving long-term therapy with glucocorticoids have rapid loss of bone; those who do, need to be identified for consideration of medication adjustments. Bone mass also is reduced in some patients with asymptomatic primary hyper-parathyroidism, that has been diagnosed as a result of multi-phasic screening tests. Whether these latter patients undergo parathyroidectomy may depend on there being a progressive loss of bone, presumed to be parathyroid hormone-dependent, and treatable by correction of the hyper-parathyroidism. Lastly, since not all patients with vertebral abnormalities have significant osteoporosis, identifying those who do, enables the costs and risks of follow-up and therapy to be directed and limited to those that require more extensive intervention.
Bone mass loss has also been associated with long-term (i.e., longer than 2 years) use of Depo-Provera Contraceptive Injection (CI) therapy. Depo-Provera CI therapy is indicated for the prevention of pregnancy. It reduces serum estrogen levels and is associated with significant loss of BMD as bone metabolism accommodates to a lower estrogen level. According to the prescribing information for Depo-Provera, BMD should be evaluated when a woman needs to continue to use Depo-Provera CI long-term (i.e., longer than 2 years). This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if use of Depo-Provera CI by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life. In both adults and adolescents, the decrease in BMD appears to be at least partially reversible after Depo-Provera CI is discontinued and ovarian estrogen production increases (Pfizer, Inc., 2006).
The rationale for densitometry lies in the assumption that the strength or resistance of a bone to fracture is closely related to the mass of the mineral present in the bone; the lower the bone density, the greater the fracture risk. Although BMD can be measured by some multi-purpose imaging devices such as quantitative computed tomography (QCT) scanners, specific densitometry tests emit lower radiation and cost less. Single-photon absorptiometry (SPA), dual-photon absorptiometry (DPA), and dual-energy radiographic (x-ray) absorptiometry, (DEXA, DXA, DER, DRA) all calculate bone mass on the basis of tissue absorption of photons derived from either a radionuclide or an x-ray tube.
In the past, SPA and DPA were the most commonly used methods of measurement. These methods have largely been replaced by DEXA. Single-photon absorptiometry measures the distal third of the radius which is composed mainly of cortical bone whereas most non-traumatic fractures occur in the axial skeleton (spine) and proximal femur (hip), which have a significant amount of trabecular bone. Measuring trabecular bone mass in the ultradistal radius or calcaneus (heel) has been more difficult because of bone tapering and irregularities.
Dual photon absorptiometry measures trabecular bone but costs more, takes longer, and the patient must lie down; apparent changes in serial DPA results must be carefully interpreted because the aging of the Gd-153 source can result in an apparent increase in bone mineral content.
Dual-energy radiographic (x-ray) absorptiometry, available since 1987, is the current standard of care for bone mass measurement. It uses an x-ray tube, instead of an isotope to generate dual energy photons, resulting in higher image resolution and greater speed than DPA. DEXA has replaced DPA; previous DPA manufacturers have switched to producing DEXA scanners.
Some authorities have advocated annual bone mineral density screening. The International Society for Clinical Densitometry, an association of providers with an interest in bone density measurement, recommends annual testing to detect continued bone loss in patients receiving treatment. The position statement included a series of recommendations, but did not provide analysis to support these recommendations. In addition, the American College of Radiology has recommended annual testing in patients receiving treatment.
However, the clinical literature on the accuracy and precision of bone density measurement does not support a recommendation for annual screening. Erlichman and Holohan (1996) reviewed the literature on commonly used bone densitometry techniques, including DEXA. They found that, although reviews of recent studies report DEXA accuracy error from 3 to 6 %, other data indicate that DEXA accuracy error of ashed bone specimens of 9 %. (Measurements obtained by densitometers are compared with an independent standard measurement of bone mass, such as ashed bone sections. The accuracy error is determined by how much the measurement varies from this accepted or "true" value.)
Dual-energy radiographic (x-ray) absorptiometryscans of the femur have a precision error from 0.5 % to 3 %. Precision error is the variability in the measurements occurring with repeated measurements of the same object. A technique's precision is critical for serial measurements that correctly document bone loss over time. Factors such as patient positioning, calibration and standardization procedures, and differences in operator technique can result in large measurement variations. The precision of measurements is reduced outside of the controlled conditions of a clinical trial setting.
The requisite minimum intervals between measurements that are necessary to reliably detect a reduction in bone mass are related to the precision attainable with current instruments and the rate of bone mass loss, assuming that the accuracy of the instrument is invariable. If one assumed a 1 % precision error, an annual rate of bone loss of 3 % would be required to reliably detect bone mass loss after 1 year.
But Erlichman and Holohan (1996) explained that it is unlikely that yearly densitometry would be clinically indicated given the fact that 1 % precision error is rarely attained and that a 3 % annual loss in bone mass would be distinctly uncommon. Precision errors in the range of 2 to 3 % and annual bone mass losses of 1 to 2 % are parameters more representative of published data. In those instances, the minimum interval between densitometry measures necessary to document bone mass loss would be between 3.7 and 6 years.
Furthermore, there are no clinical data that demonstrate improved outcomes in osteoporosis patients who are screened annually. Clinical trials of the bisphosphonate alendronates for the treatment of osteoporosis have found that failure to respond to therapy is a rare event.
A clinical practice guideline on osteoporosis in men issued by the American College of Physicians (ACP) (Qaseem et al, 2008) recommended that physicians periodically assess elderly men for risk factors for osteoporosis. Although osteoporosis is often viewed as a disease of women, studies show that osteoporotic factures in men are associated with significant morbidity and mortality, resulting in substantial disease burden, death, and healthcare costs. The prevalence of osteoporosis is estimated to be 7 % in white men, 5 % in black men, and 3 % in Hispanic men. Data on prevalence of osteoporosis in Asian-American men and other ethnic groups are lacking. The guideline recommended that clinicians assess risk factors for osteoporosis in older men and obtain a DXA scan for men at increased risk for osteoporosis who are candidates for drug therapy. Risk factors for osteoporosis in men include age greater than 70 years, low body weight (body mass index [BMI] less than 20 to 25 kg/m2 or lower), weight loss (greater than 10 %), lack of regular physical activity, such as walking, climbing stairs, carrying weights, housework, or gardening, use of oral corticosteroids, previous osteoporotic fracture, and androgen deprivation therapy. The ACP also recommended further research to evaluate osteoporosis screening tests in men and that, presently, non-DXA tests are either "too insensitive or have insufficient data to reach conclusions."
Metabolic bone diseases that fall under the generic term "renal osteodystrophy" represent abnormal development of bone and major long-term complications in end-stage renal disease. Chronic kidney disease (CKD) is associated with an increased risk of fracture. Decreased bone mass and disruption of micro-architecture occur early in the course of CKD and worsens with the progressive decline in renal function so that at the time of initiation of dialysis at least 50 % of patients have had a fracture. Despite the excess fracture risk, and the associated increases in morbidity and mortality, little is known about the factors that are associated with an increase in fracture risk; and the utility of bone mass measurements in patients with CKD is unclear. Jamal (2010) reviewed the epidemiology and etiology of fractures in patients with CKD; and summarized published data that described the association between bone mass measurements and fracture in patients with CKD. Patients with CKD suffer from fractures due to impairments in bone quantity, bone quality, as well as abnormalities of neuromuscular function. The complex etiology of fractures combined with the technical limitations of BMD testing, both by DEXA and by peripheral QCT, limits the clinical utility of bone mass measurements for fracture prediction in CKD; this is particularly true among patients with stages 4 and 5 CKD. As such, clinicians should not routinely order BMD testing in patients with CKD. The author concluded that further research, to ascertain if BMD together with other non-invasive measures to assess bone strength can predict fracture, is needed.
The conclusions of this assessment are consistent with those of an earlier assessment of BMD testing for renal disease prepared by the Agency for Health Care Policy and Research (Ehrlichman and Holohan, 1996), which concluded that BMD measurements are not able to differentiate uremic bone diseases or predict fracture risk in patients with renal osteodystrophy. As a result, BMD measurements currently do not provide useful information that could support therapeutic decisions in the management of these patients.
The U.S. Preventive Services Task Force updated its 2002 recommendation on screening for osteoporosis (USPSTF, 2011). The USPSTF evaluated evidence on the diagnostic accuracy of risk assessment instruments for osteoporosis and fractures, the performance of DEXA and peripheral bone measurement tests in predicting fractures, the harms of screening for osteoporosis, and the benefits and harms of drug therapy for osteoporosis in women and men. The USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year old white woman who has no additional risk factors (Grade B recommendation). The USPSTF concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men.
The European Association of Urology’s guidelines on “Male hypogonadism” (Dohle et al, 2012) states that “In men with an abnormal BMD, BMD measurements should be repeated 6 and 12 months after the start of TRT [testosterone replacement therapy] and thereafter annually”. (Level of evidence: 4 [Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities]; Grade of recommendation: C [Made despite the absence of directly applicable clinical studies of good quality]).
Dual X-ray and laser (DXL) is a technique that is currently being examined as a means for bone mass measurement. This approach employs 2 X-ray beams in conjunction with a laser. This technique supposedly has the advantage of filtering out any influence that adipose tissue inside and outside the bone may have on the accuracy of DXA measurements; DXL has been studied mainly on the heel.
Kullenberg and Falch (2003) compared the prevalence of osteoporosis (using a T-score threshold of -2.5 for heel measurements) by DXL technology with that obtained by DXA measurements at the femoral neck, spine and forearm. The prevalence of osteoporosis for women aged 50 years or older was 28 % for DXL measurements of the heel bone and 30, 22 and 32 % for DXA measurements of the lumbar spine, femoral neck and forearm, respectively. Bone mineral density was also measured by DXL in the heel bone and by DXA in spine and femoral neck in 251 women (mean age of 62 +/- 14.5 years) when attending an osteoporosis clinic. The sensitivity and specificity for osteoporosis and osteopenia for the DXL measurements were calculated assuming a low T-score at the spine or femoral neck as the criterion for a correct diagnosis. The sensitivity was found to be 80 % for osteoporosis and 82 % for osteopenia and the specificity was 82 % for osteoporosis and 89 % for osteopenia. The authors concluded that DXL measurement at the heel bone, using a T-score threshold of -2.5 for classification of osteoporosis, is in concordance with the World Health Organization (WHO) definition of osteoporosis.
Martini et al (2004) evaluated the reproducibility and the diagnostic accuracy of a new device for the assessment of BMD of the heel (DXL Calscan). This technique associates X-ray absorptiometry to the measure of heel thickness with a laser beam. The calcaneus BMD, calcaneus quantitative sonography (QUS), and lumbar spine and total-body BMD, were evaluated in 40 post-menopausal women. On the basis of the BMD T-score measured by DXA of L2 to L4, 20 women were classified as osteoporotic and 20 women were considered non-osteoporotic according to the WHO classification. The short-term coefficient of variation of the DXL was 2.4 % and 1.7 % in osteoporotic and non-osteoporotic women, respectively. The calcaneus BMD was lower in osteoporotic than in non-osteoporotic women. Among osteoporotic patients, 14 patients had a T-score lower than -2.5 at Calscan, whereas only 4 patients classified as non-osteoporotic based on the lumbar spine BMD were mis-classified by Calscan. In these patients, the sensitivity and specificity of heel ultrasound measurements were 70 % and 85 %, respectively. The DXL BMD was highly correlated with the total-body BMD, Stiffness at the calcaneus, and the L2 to L4 BMD. The authors concluded that the Calscan DXL appeared easy to use; the time of examination was relatively short; the reproducibility was sufficiently good; and the diagnostic accuracy and relationships with other devices were good.
Salminen and colleagues (2005) examined the relationship between calcaneal and axial BMD in an elderly female population. These researchers also investigated the influence of changing the reference populations on T-score values. Bone mineral density was determined in 388 women (mean age of 73 years) participating in a cross-sectional study. BMD values were determined at the left hip and the lumbar spine, L1 to L4, using Hologic QDR 4500 equipment for DXA. The calcaneal measurements were made with DEXA-T, a device using a DXL technique that combines DXA measurement with measurement of the heel thickness using a laser reflection technique. DEXA-T is an older version of the Calscan DXL device now commercially available. T-score values were calculated for hip measurements with both the original reference population of the Hologic device and the NHANES III reference population. T-scores for heel measurements were calculated with the original reference population of the peripheral device and the Calscan database, a new calcaneal reference population. Changing the reference populations had a great influence on both the heel and the hip T scores, especially those of the femoral neck where the percentage of subjects identified as osteoporotic decreased from 53 % to 23 %. The authors concluded that, with the NHANES III and the larger Calscan database, using the cut-off point of -2.5 SD, the heel measurements had optimal accuracy for detecting osteoporosis at either the combination of the lumbar spine and the femoral neck or the combination of the lumbar spine, the femoral neck, the total hip and the trochanter. BMD measurements of the calcaneus with DXL correlated fairly well with measurements at axial sites at the group level, while in individual subjects large deviations were observed between all the measured sites. They also stated that the influence of the reference populations on the T-scores is substantial when different DXA methods are being compared; the total number of subjects classified as osteoporotic varied from 7 % to 53 % between the sites and with different reference populations.
de Klerk et al (2009) compared BMD expressed in T-scores measured by DXA and DXL (Calscan). The aim of this study was to define threshold T-scores on the Calscan that could exclude or predict osteoporosis correctly in comparison with DXA. Patients 50 years of age or older attending the emergency department with a fracture were offered osteoporosis screening and enrolled in this study. BMD was measured at the hip and spine using DXA and at the calcaneus using Calscan. A T-score measured by DXA less than or equal to -2 SD below the reference population was defined as manifest osteoporosis and was the treatment threshold. During a 10-month study period, 182 patients were screened with both devices. The mean DXA-T-score was -1.63 SD (range of -4.9 to 2.1) and Calscan T-score -1.91 SD (range of -5.3 to 1.4). There was a significant correlation between both devices (r = 0.47, p < 0.01). Using an upper threshold for the Calscan T-score of -1.3 SD, 47 patients could be classified as non-osteoporotic with 89.3 % sensitivity (95 % CI: 80.0 to 95.3 %). Using a lower threshold for the Calscan T-score of -2.9 SD, 34 patients could be classified by the Calscan as osteoporotic with 90.7 % specificity (95 % CI: 83.5 to 95.4). The remaining 101 patients could only be correctly classified by DXA-T-scores. The authors concluded that although DXA is the established modality worldwide in measuring BMD it is restricted to specialized centers. Peripheral bone densitometers like the Calscan are widely available. When BMD measurements with DXA were compared to Calscan measurements it was possible to correctly classify 81 of 182 patients based on the Calscan T-score. Of these 81 patients 34 could be classified as manifest osteoporotic and 47 as non-osteoporotic. Thus, the authors concluded that Calscan seems to be a promising technique that might be used as a screening device, especially when DXA is not easily available.
Yumru et al (2009) compared DXL heel measurements of BMD and DEXA total hip and lumbar spine BMD measurements for their ability to detect osteoporosis and osteopenia according to WHO criteria. The study included 164 women aged 40 to 83 years. DXL heel measurements were recorded for all patients and 89 of the women underwent DEXA. For DXL heel measurements/DEXA lumbar spine measurements, the relative sensitivity was 50 %, relative specificity was 97 % and relative reliability (Kappa score) was 0.55 for osteoporosis detection. For detecting osteoporosis or osteopenia, the relative sensitivity increased to 86 % but the relative specificity reduced to 38 % and the relative reliability was considerably lower (Kappa score 0.21). The authors concluded that although previous studies have shown DXL heel measurement to be a good technique in the diagnosis and assessment of osteoporosis based on BMD, particularly for fast, cost-effective bone scanning, they suggested that there are currently insufficient data to prove its use as a standard measurement technique for BMD.
In a systematic review for an American College of Physicians (ACP)’s guideline on “Screening for osteoporosis in men” (Liu et al, 2008) evaluated (i) risk factors for osteoporotic fracture in men that may be mediated through low BMD, and (ii) the performance of non-DXA tests in identifying men with low BMD. Studies identified through the MEDLINE database (1990 to July 2007) were included for analysis. Articles that assessed risk factors for osteoporotic fracture in men or evaluated a non-DXA screening test against a gold standard of DXA were selected. Researchers performed independent dual abstractions for each article, determined performance characteristics of screening tests, and assessed the quality of included articles. A published meta-analysis of 167 studies evaluating risk factors for low BMD-related fracture in men and women found high-risk factors to be increased age (greater than 70 years), low body weight (BMI less than 20 to 25 kg/m2), weight loss (greater than 10 %), physical inactivity, prolonged corticosteroid use, and previous osteoporotic fracture. An additional 102 studies assessing 15 other proposed risk factors were reviewed; most had insufficient evidence in men to draw conclusions. Twenty diagnostic study articles were reviewed. At a T-score threshold of -1.0, calcaneal ultrasonography had a sensitivity of 75 % and specificity of 66 % for identifying DXA-determined osteoporosis (DXA T-score, -2.5). At a risk score threshold of -1, the Osteoporosis Self-Assessment Screening Tool had a sensitivity of 81 % and specificity of 68 % to identify DXA-determined osteoporosis. The authors concluded that key risk factors for low BMD-mediated fracture include increased age, low body weight, weight loss, physical inactivity, prolonged corticosteroid use, previous osteoporotic fracture, and androgen deprivation therapy. Moreover, they stated that non-DXA tests either are too insensitive or have insufficient data to reach conclusions.
Indeed, the AAP’s clinical practice guideline on “Screening for osteoporosis in men” (Qaseem et al, 2008) recommended that clinicians obtain dual-energy x-ray absorptiometry for men who are at increased risk for osteoporosis and are candidates for drug therapy. Furthermore, UpToDate reviews on “Screening for osteoporosis” (Kleerekoper, 2012) and “Osteoporotic fracture risk assessment” (Lewiecki, 2012) mentioned the use of dual energy x-ray absorptiometry, but not DXL.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
Ultrasound bone density measurement and interpretation, peripheral site(s), any method [not covered for monitoring osteoporosis drug therapy]
Computerized tomography, bone mineral density study, 1 or more sites [not covered for monitoring osteoporosis drug therapy]
77080 - 77081
Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites
CPT codes not covered for indications listed in the CPB:
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment
Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)
Bone density (bone mineral content) study, one or more sites; single photon absorptiometry
Bone density (bone mineral content) study, one or more sites; dual photon absorptiometry, one or more sites
HCPCS codes covered if selection criteria are met:
Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel) [not covered for monitoring osteoporosis drug therapy]
Other HCPCS codes related to the CPB:
Injection, medroxyprogesterone acetate, 50 mg
Injection, medroxyprogesterone acetate, 1 mg
Injection, leuprolide acetate (for depot suspension), per 3.75 mg
Goserelin acetate implant, per 3.6 mg
Leuprolide acetate (for depot suspension), 7.5 mg
Leuprolide acetate, per 1 mg
Leuprolide acetate implant, 65 mg
ICD-9 codes covered if selection criteria are met:
242.00 - 242.9
Thyrotoxicosis with or without goiter
252.00 - 252.08
Other ovarian failure
Other testicular hypofunction
Androgen insensitivity syndrome
345.00 - 345.91
Epilepsy and recurrent seizures
627.0 - 627.9
Menopausal and postmenopausal disorders
733.10 - 733.19
Post traumatic seizures
805.00 - 806.9
Fracture of vertebral column
Hormone replacement therapy (postmenopausal)
Asymptomatic postmenopausal status (age-related) (natural)
Long-term (current) use of steroids [glucocorticoid therapy]
ICD-9 codes not covered for indications listed in the CPB:
403.00 - 403.91 404.00 - 404.93
Hypertensive chronic kidney disease
580.0 - 593.9
Disease of kidney [chronic]
753.0 - 753.3
Congenital anomalies of kidney
Other ICD-9 codes related to the CPB:
Disorder of bone and cartilage, unspecified [osteopenia]
Loss of weight
Long-term (current) use of other medications [anticonvulsant therapy] [osteoporosis drug therapy (covered for DEXA only)]
Lack of physical exercise
Special screening for osteoporosis [routine examination]
Body Mass Index less than 19, adult
The above policy is based on the following references:
U.S. Department of Health and Human Services, Center for Medicare and Medicaid Services (CMS). Medicare Program; Medicare Coverage and Payment for Bone Mass Measurements. 42 CFR Part 410, 63 Fed. Reg. 121. June 24, 1998: 34320-34328.
Hailey D, Sampietro-Colom L, Marshall D, et al. Statement of findings. INAHTA project on the effectiveness of bone density measurement and associated treatments for prevention of fractures. Edmonton, AB: Alberta Heritage Foundation for Medical Research (on behalf of the International Network of Agencies for Health Technology Assessment (INAHTA); 1996.
Green CJ, Bassett K, Foerster V, Kazanjian A. Bone mineral density testing: Does the evidence support its selective use in well women? BCOHTA 97:2T. Vancouver, BC: Office of Health Technology Assessment, Centre for Health Services and Policy Research, University of British Columbia (BCOHTA); 1997.
Erlichman M, Holohan T. Bone densitometry. In Nuclear Medicine: Diagnosis and Therapy. Harbert, Eckelman, Neurnann, eds. New York, NY: Thieme Medical Publishers, Inc.; 1996: 865-880.
Ehrlichman M, Holohan T. Bone densitometry: Patients with end-stage renal disease. Health Technology Assessment No. 8. AHCPR Pub. No. 96-0040. Rockville, MD: Agency for Health Care Policy and Research (AHCPR); March 1996.
Hailey D, Sampietro-Colom L, Marshall D, et al. The effectiveness of bone density measurement and associated treatments for prevention of fractures: An international collaborative review. Int J Technol Asses Health Care. 1998;14(2):237-254.
Homik J, Hailey D. Quantitative ultrasound for bone density measurement. HTA 11. Edmonton, AB: ALberta Heritage Foundation for Medical Research (AHFMR); 1998.
Espallargues M, Dolors Estrada M, Sola M, et al. Guidelines for the indication of bone densitometry in the assessment of fracture risk. BR99005. Barcelona, Spain: Catalan Agency for Health Technology Assessment and Research (CAHTA); 1999.
Homik J, Hailey D. Selective testing with bone density measurement. Health Technology Brief, HTB-4. Edmonton, AB: Alberta Heritage Foundation for Medical Research (AHFMR); 1999.
National Institutes of Health (NIH). Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1-45.
American Academy of Orthopaedic Surgeons, American College of Obstetricians and Gynecologists, American Geriatrics Society, American College of Radiology, American College of Rheumatology, American Academy of Physical Medicine and Rehabilitation, American Association of Clinical Endocrinologists, National Osteoporosis Foundation, The Endocrine Society and the American Society for Bone and Mineral Research. Physician's guide to prevention and treatment of osteoporosis. Belle Mead, NJ: Excerpta Medica, Inc.; 1999.
American College of Obstetricians and Gynecologists (ACOG), Committee on Gynecologic Practice. Bone density screening for osteoporosis. ACOG Committee Opinion No. 270. Washington, DC: ACOG; 2002.
North American Menopause Society. Management of postmenopausal osteoporosis: Position statement of The North American Menopause Society. Menopause. 2002;9(2):84-101.
U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women. In: Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 3rd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2000-2002. Available at: http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm. Accessed September 24, 2002.
Miller PD, Njeh CF, Jankowski LG, et al. What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis. J Clin Densitom. 2002;5 Suppl:S39-S45.
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA. 2002;288(15):1889-1897.
Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature. Osteoporos Int. 2001;12:811-822.
Rossignol M, Moride Y, Perreault S, et al. Osteoporosis and fractures among people aged 65 and over: Recommendations for an integrated framework for action in Quebec. AETMIS 01-4 RE. Montreal, QC: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2001.
Nelson HD, Helfand M. Screening for postmenopausal osteoporosis. Preventive Services Task Force Systematic Evidence Review No. 17. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2002.
Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(6):529-541.
Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: Diagnosis and monitoring. Evidence Report/Technology Assessment No. 28. AHRQ Pub. No. 01-E032. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ): 2002.
Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: A systematic review and cost-utility analysis. Health Technol Assess. 2002;6(29).
Institute for Clinical Systems Improvement (ICSI). Densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women. Bloomington, MN: ICSI; 2000.
Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Bone mineral density screening. Pre-assessment. No 18. Ottawa, ON: CCOHTA; 2003.
International Society of Clinical Densitometry (ISCD). Bone mineral density testing. Official Positions. West Hartford, CT: ISCD; November 1, 2003. Available at: http://www.iscd.org/Visitors/official.cfm. Accessed January 26, 2004.
Miller PD. Bone mass measurements. Clin Geriatr Med. 2003;19(2):281-297, vi.
Aidelsburger P, Hessel F, Wasem J. The value of ultrasound diagnostic technologies in the prevention of fractures in patients with osteoporosis (Early diagnosis of the risk for fractures) [summary]. Cologne, Germany: German Agency of Health Technology Assessment at German Institute for Medical Documentation and Information (DAHTA) (DIMDI); 2003.
BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Vertebral assessment using dual-energy x-ray absorptiometry for osteoporotic fracture risk assessment. TEC Assessment Program. Chicago, IL: BCBSA; December 2004; 19(14). Available at: http://www.bcbs.com/tec/vol19/19_14.html. Accessed February 18, 2005.
BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Ultrasonography of peripheral sites for selecting patients for pharmacologic treatment for osteoporosis. TEC Assessment Program. Chicago IL: BCBSA; 2002;17(5). Available at: http://www.bcbs.com/tec/vol17/17_05.html. Accessed February 18, 2005.
Hagenfeldt K, Johansson C, Johnell O, et al. Osteoporosis - prevention, diagnosis and treatment. SBU Report No. 165. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care (SBU); 2003.
Elliott ME, Binkley N. Evaluation and measurement of bone mass. Epilepsy Behav. 2004;5 Suppl 2:S16-S23.
American Gastroenterological Association. American Gastroenterological Association medical position statement: Celiac sprue. Gastroenterology. 2001;120(6):1522-1525.
Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77(5):453-468.
Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9(6):544-564.
Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003;67(7):1521-1526.
Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer. 2004;100(5):892-899.
Parrella A, Mundy L, Merlin T, Hiller J. DXL Calscan bone densitometer to measure bone mineral density of the os calcis. Horizon Scanning Prioritising Summary - Volume 9. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); 2005.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
Alaedini A, Green PH. Narrative review: Celiac disease: Understanding a complex autoimmune disorder. Ann Intern Med. 2005;142(4):289-298.
BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Screening for vertebral fracture with dual X-ray absorptiometry. TEC Assessment Program. Chicago, IL: BCBSA; February 2006;20(14). Available at: http://www.bcbs.com/betterknowledge/tec/vols/20/20_14.html. Accessed October 8, 2007.
Bachrach LK. Measuring bone mass in children: Can we really do it? Horm Res. 2006;65 Suppl 2:11-16.
Sullivan T, Hiller J. DXL Calscan bone densitometer to measure bone mineral density of the os calcis. Horizon Scanning Prioritising Summary - Volume 6. Update No. 2. Adelaide, SA: National Horizon Scanning Unit, Adelaide Health Technology Assessment; June 2006.
Adelaide Health Technology Assessment on behalf of National Horizon Scanning Unit (HealthPACT and MSAC). Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis; Horizon scanning prioritising summary - Volume 13. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); June 2006.
Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat (MAS). Utilization of DXA bone mineral densitometry in Ontario. Health Technology Literature Review. Toronto, ON: MAS; November 2006.
Center for Medicare and Medicaid Services (CMS). NCD for bone (mineral) density studies (150.3). Medicare Coverage Database. Baltimore, MD: CMS; effective January 1, 2007.
Dunfield L, Mierzwinski-Urban M, Hodgson A, Banks R. Diagnostic performance and cost effectiveness of technologies to measure bone mineral density in postmenopausal women. Technology Report No. 94. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); December 2007. Available at: http://cadth.ca/index.php/en/hta/reports-publications/search/publication/771. Accessed January 25, 2008.
McDevitt H, Ahmed SF. Quantitative ultrasound assessment of bone health in the neonate. Neonatology. 2007;91(1):2-11.
Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006;8(1):28-39.
Liu H, Paige NM, Goldzweig CL, et al. Screening for osteoporosis in men: A systematic review for an American College of Physicians guideline. Ann Intern Med. 2008;148(9):685-701.
Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(9):680-684.
Ebeling PR. Clinical practice. Osteoporosis in men. NEJM. 2008;358(14):1474-1482.
Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med. 2009;36(4):366-375.
Jamal SA. Bone mass measurements in men and women with chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(4):343-348.
Nelson HD, Haney EM, Chou R, et al. Screening for osteoporosis: Systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 77. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2010.
IQWiG. Osteodensitometry in primary and secondary osteoporosis. Summary. D07-01. Cologne, Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2010.
U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356-364.
Canadian Agency for Drugs and Technologies in Health (CADTH). T-score as a measurement to assess the 10-year fracture risk: A review of the clinical evidence. Ottawa, ON: CADTH; 2011.
Dohle GR, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism. Arnhem, The Netherlands: European Association of Urology; February 2012.
Kullenberg R, Falch JA. Prevalence of osteoporosis using bone mineral measurements at the calcaneous by dual X-ray and laser (DXL). Osteoporosis Int. 2003; 14(10):823-827.
Martini G, Valenti R, Gennari L, et al. Dual X-ray and laser absorptiometry of the calcaneus: Comparison with quantitative ultrasound and dual-energy X-ray absorptiometry. J Clin Densitom. 2004;7(3):349-354.
Salminen H, Saaf M, Ringertz H, Strender LE. Bone mineral density measurement in the calcaneus with DXL: Comparison with hip and spine measurements in a cross-sectional study of an elderly female population. Osteoporos Int. 2005;16(5):541-551.
Liu H, Paige NM, Goldzweig CL, et al. Screening for osteoporosis in men: A systematic review for an American College of Physicians guideline. Ann Intern Med. 2008;148(9):685-701.
Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(9):680-684.
de Klerk G, van der Velde D, van der Palen J, et al. The usefulness of dual energy X-ray and laser absorptiometry of the calcaneus versus dual energy X-ray absorptiometry of hip and spine in diagnosing manifest osteoporosis. Arch Orthop Trauma Surg. 2009;129(2):251-257.
Yumru AE, Bozkurt M, Aksoy HE, et al. Comparison of dual X-ray laser and dual energy X-ray absorptiometry techniques of osteodensitometry. J Int Med Res. 2009;37(2):541-546.
Kleerekoper M. Screening for osteoporosis. UpToDate [online serial]. Waltham, MA: UpToDate; updated September 2012.
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.